Bethlehem, PA-(Business wire-ABEC, a global provider of engineering solutions and services for biotechnology manufacturing, today announced that mAbxience will equip its state-of-the-art cGMP facility in Leon, Spain with an additional ABEC 4,000 LCSR bioreactor. After successfully delivering the first 4,000 LCSR bioreactor in 2021, mAbxience has re-selected ABEC’s innovative disposable technology to increase its CDMO business and capacity.
After being approved in Europe, Canada, Japan, etc. in April 2022, the US Food and Drug Administration (FDA) was developed by mAbxience and represents the third biosimilar, Bevacizumab Marie’s Biologics Approval Application (BLA). ) Approved. Combining innovation with state-of-the-art R & D technology approved in the United States, mAbxience is committed to improving patient access to critical treatments. With an additional 4,000 LCSR bioreactor, mAbxience enables even greater cell culture productivity and faster process transfer scale-up.
“The continued growth of mAbxience in the biosimilar market demonstrates the value of strategic partnerships with ABEC and others.” Emmanuelle Lepine, CEO of mAbxience, said: “As we look to the future of healthcare, we are excited to be at the forefront of sustainable practices that improve access to critical medicines.”
“ABEC continues to lead the industry in bringing scale and productivity to disposable manufacturing.” Scott Pickering, Chairman and Chief Executive Officer of ABEC, said. “We are proud to continue to support the growth of mAbxience with our innovative CSR technology.”
About ABEC
Since 1974, ABEC has been a global leader in the biotechnology industry, providing process solutions and services designed for the manufacturing industry. The majority of the world’s pharmaceutical and biotechnology companies are ABEC customers. It features many of today’s major therapies manufactured by processes and equipment designed, manufactured, installed, and serviced by ABEC. ABEC’s unique value is based on years of experience, complete internal capabilities, a custom and flexible approach, and long-term reliability. Whether you’re adding capacity or improving your existing facilities, ABEC’s turnkey solutions and support services reduce overall costs and time to market while maximizing productivity. For more information on ABEC, please visit abec.com, send an email to info @ ab ec.com and follow us on LinkedIn.
About mAbxience
MAbxience is a fully integrated global biopharmacy company specializing in the development, manufacture and commercialization of monoclonal antibodies and CDMO services, forming part of the pharmaceutical group Insud Pharma. Founded in 2010, mAbxience operates three state-of-the-art facilities in Spain and Argentina. mAbxience is working on several biopharmacy products that span a variety of therapeutic areas. In 2014, mAbxience launched the first biosimilar, rituximab (product code: RTXM83-MB01). It is currently approved and sold in various markets around the world. The second product, bevacizumab (product code: BEVZ92-MB02), was first developed and launched in Latin America in 2016. mAbxience is committed to the quality, safety and efficacy of medicines. The mAbxience team is passionate about patient care and increased access to biopharmacy worldwide. Our mission is to improve patient access to quality treatments for conditions that require costly medications and to actively contribute to the sustainability of the healthcare system. Founded by Dr. Hugo Sigman and Dr. Silvia Gold, the Insud Pharma Group has more than 40 years of experience in the pharmaceutical industry and employs more than 6,000 professionals worldwide.
Commentaires
Enregistrer un commentaire